Children’s Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma with hu14.18-IL2 (APN301)

APEIRON Biologics AG and the Children’s Oncology Group today announced to collaborate in a phase II study with Apeiron’s APN301 in pediatric neuroblastoma patients.Neuroblastoma can be one of the most difficult to treat childhood cancers with about 650 to 750 children diagnosed each year in the U.S. and the E.U., respectively.

Press release